1Department of Critical Care Medicine, Seoul National University Boramae Medical Center, Seoul, Korea. 2Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea. 3Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea. 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. 5Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea. 6Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 7Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Crit Care Med. 2017 Jan;45(1):47-57. doi: 10.1097/CCM.0000000000002012.
Severe acute kidney injury requiring continuous renal replacement therapy is associated with a high risk of early mortality. Our objectives were to identify a cohort of early survivors and to follow their renal progress and long-term mortality.
Multicenter, observational, retrospective cohort study.
ICUs in tertiary academic hospitals in Korea.
From 2009 to 2013, we identified 1,764 severe acute kidney injury patients who were started on continuous renal replacement therapy at four hospitals. Of these, we identified 331 survivors for whom we could identify renal function at baseline and at 3 months.
None.
The 331 patients were separated into two groups based on their renal function at 3 months after the start of continuous renal replacement therapy. Those who displayed significant deterioration in renal function compared to baseline, defined as greater than or equal to 50% increase in serum creatinine or greater than or equal to 35% decrease in the estimated glomerular filtration rate, or those who continued to receive renal replacement therapy were designated as a "3-month chronic kidney disease progression" group. Those with a return to baseline, less than 50% increase in serum creatinine or less than 35% decrease in the estimated glomerular filtration rate, were designated as a "3-month chronic kidney disease nonprogression" group. The acute kidney injury patients requiring continuous renal replacement therapy showed a higher risk of progression to end-stage renal disease compared to that of stage 3 chronic kidney disease patients who did not undergo an acute kidney injury episode, even if the acute kidney injury was recovered at 3 months after continuous renal replacement therapy initiation. Furthermore, "3-month chronic kidney disease progression" was associated with a high risk of progression to end-stage renal disease and long-term mortality over a median follow-up period of 12.7 (3.8-33.2) and 20.4 (7.5-39.7) months, respectively. Older age, higher baseline serum creatinine levels, and higher blood urea nitrogen concentrations at continuous renal replacement therapy initiation, and lower 24-hour urine output after continuous renal replacement therapy initiation are associated with an increased risk of "3-month chronic kidney disease progression."
Renal functional assessment at 3 months after continuous renal replacement therapy initiation can be useful in predicting progression to end-stage renal disease and long-term mortality. Furthermore, continuous close monitoring and management of acute kidney injury patients requiring continuous renal replacement therapy are required, even in those with recovered renal function.
需要连续肾脏替代治疗的严重急性肾损伤与早期死亡率高相关。我们的目标是确定一组早期幸存者,并随访他们的肾脏进展和长期死亡率。
多中心、观察性、回顾性队列研究。
韩国三家三级学术医院的 ICU。
2009 年至 2013 年,我们在四家医院确定了 1764 名开始连续肾脏替代治疗的严重急性肾损伤患者。其中,我们确定了 331 名幸存者,可确定他们在基线和 3 个月时的肾功能。
无。
根据连续肾脏替代治疗开始后 3 个月时的肾功能,将 331 名患者分为两组。那些与基线相比肾功能明显恶化的患者,定义为血清肌酐增加大于等于 50%或估计肾小球滤过率降低大于等于 35%,或继续接受肾脏替代治疗的患者被指定为“3 个月慢性肾脏病进展”组。那些恢复到基线,血清肌酐增加小于 50%或估计肾小球滤过率降低小于 35%的患者被指定为“3 个月慢性肾脏病非进展”组。与未发生急性肾损伤的急性肾损伤患者相比,需要连续肾脏替代治疗的急性肾损伤患者进展为终末期肾病的风险更高,即使在连续肾脏替代治疗开始后 3 个月恢复了急性肾损伤。此外,“3 个月慢性肾脏病进展”与中位随访 12.7(3.8-33.2)和 20.4(7.5-39.7)个月后进展为终末期肾病和长期死亡率高相关。年龄较大、基线血清肌酐水平较高、连续肾脏替代治疗开始时血尿素氮浓度较高以及连续肾脏替代治疗开始后 24 小时尿量较低与“3 个月慢性肾脏病进展”风险增加相关。
连续肾脏替代治疗开始后 3 个月的肾功能评估可用于预测进展为终末期肾病和长期死亡率。此外,即使肾功能恢复,也需要对需要连续肾脏替代治疗的急性肾损伤患者进行持续密切监测和管理。